- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02293551
A Study of Lispro Formulations in Healthy Participants
Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations
The purposes of this study are to determine:
Part A
- How quickly your body absorbs, breaks down and gets rid of the different formulations of insulin lispro compared to insulin lispro alone formulation.
- The safety of insulin lispro in different formulations and any side effects that might be associated with it.
Part B:
- How much insulin lispro from different dose ranges is found in the bloodstream using a test insulin lispro formulation (selected from Part A).
- The safety of insulin lispro in different formulations and any side effects that might be associated with it.
Participants may only enroll in one part. The study is expected to last up to 10 weeks for each part.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Overtly healthy males or females (nonchildbearing potential and with absent cyclical hormonal changes), as determined by medical history and physical examination
Exclusion Criteria:
- Have a fasting plasma glucose less than or equal to (≤) 4.0 millimole per liter (mmol/L) at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: Lispro (A)
Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.
|
Administered SC
Other Names:
|
Experimental: Part A: Lispro (B)
Formulation B: Single dose of lispro administered SC in one of five periods.
|
Administered SC
Other Names:
|
Experimental: Part A: Lispro (C)
Formulation C: Single dose of lispro administered SC in one of five periods.
|
Administered SC
Other Names:
|
Experimental: Part A: Lispro (D)
Formulation D: Single dose of lispro administered SC in one of five periods.
|
Administered SC
Other Names:
|
Experimental: Part A: Lispro (Reference)
Reference formulation: Single dose of lispro administered SC in one of five periods.
|
Administered SC
Other Names:
|
Experimental: Part B: Lispro
Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.
|
Administered SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A and B: Pharmacokinetics: Area Under The Concentration Curve (AUC) of LY275585
Time Frame: Predose through day 1 in each period
|
Predose through day 1 in each period
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15626
- F3Z-FW-ITCA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Lispro
-
Diasome Pharmaceuticlas, Inc.RecruitingDiabetes Mellitus, Type 1United States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Germany
-
Graydon MeneillySuspendedDiabetes Mellitus | LipohypertrophyCanada
-
Joslin Diabetes CenterBoston Children's HospitalCompletedType 1 Diabetes
-
Medical University of GrazEuropean CommissionCompletedType 1 DiabetesAustria
-
Eli Lilly and CompanyCompleted